Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of online meetings, calls, and deadlines has predictably returned. But you knew this would happen, yes? To cope, we are firing up the coffee kettle and brewing a cup of stimulation. Our choice today is salted caramel mocha. Please feel free to join us. Meanwhile, time to get cracking. Here is the latest laundry list of interesting items to help you get started on your own journey today. We hope all goes well and you conquer the world. And of course, do keep in touch. …
The U.S. National Institutes of Health is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox, as current data on its effectiveness against the virus is limited, The Hill writes. The National Institute of Allergy and Infectious Diseases is sponsoring the trial, which is being led by the AIDS Clinical Trials Group. The study is currently enrolling adults and children who have been infected with monkeypox in the U.S. TPOXX was approved by the U.S. Food and Drug Administration in 2018 to treat smallpox and was authorized for use in treating monkeypox.
The FDA approved a Bristol Myers Squibb psoriasis pill, called Sotyktu, which is the first medicine of its type and the last of three potential blockbuster drugs the company sought to bring to market this year, according to BioPharma Dive. Sotyktu will compete with biologic drugs like AbbVie’s Humira and Amgen’s Enbrel, but as a pill could be more attractive to patients who do not want to inject themselves regularly. Importantly, the labeling for Sotyktu does not require patients to first try biologic drugs, giving doctors an opportunity to prescribe it widely.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect